[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353749-105":59,"doc-detail-353749-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","reassessing-cancer-risk-with-glp-1-receptor-agonists-a-comprehensive-meta-analysis-of-gastrointestinal-malignancies","Reassessing cancer risk with GLP-1 receptor agonists - a comprehensive meta-analysis of gastrointestinal malignancies","","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity, yet concerns remain about a potential link with gastrointestinal malignancies. This systematic review and meta-analysis synthesized randomized controlled trials reporting GI cancer outcomes through August 2024, totaling 93 trials and 1.85 million participants. Pooled results showed no increased overall GI cancer risk, while subgroup analyses suggested lower colorectal and liver cancer risks. Evidence was consistent in sensitivity analyses, supporting continued oncological safety with cautious interpretation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reassessing-cancer-risk-with-glp-1-receptor-agonists-a-comprehensive-meta-analysis-of-gastrointestinal-malignancies/353749/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reassessing-cancer-risk-with-glp-1-receptor-agonists-a-comprehensive-meta-analysis-of-gastrointestinal-malignancies/353749.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the review address about GLP-1 receptor agonists?","Question",{"text":112,"@type":113},"It evaluates whether GLP-1 RA use is associated with the risk of gastrointestinal cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many randomized controlled trials and participants were included?",{"text":117,"@type":113},"Ninety-three randomized controlled trials with 1.85 million participants were included.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the meta-analysis find about overall gastrointestinal cancer risk?",{"text":121,"@type":113},"GLP-1 RA use was not associated with an increased overall risk of gastrointestinal cancers (HR 0.81; 95% CI 0.68–0.96).",{"name":123,"@type":110,"acceptedAnswer":124},"Were there any cancer-specific findings in subgroup analyses?",{"text":125,"@type":113},"Yes. Colorectal and liver cancer risks were reduced in subgroup analyses, while pancreatic cancer risk was not significantly elevated; these findings should be interpreted cautiously.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},353749,1790646750,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Systematic Review PUBLISHED 10 February 2026 DOI 10.3389/fphar.2026.1736380  \nOPEN ACCESS  \nEDITED BY  \nMadhusudan Prasad Singh,  \nAll India Institute of Medical Sciences Raipur, India  \nREVIEWED BY  \nHemasri Velmurugan,  \nJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India Prachi Arunima,  \nAll India Institute of Medical Sciences Raipur, India  \n*CORRESPONDENCE  \nAdil Farooq Wali,  \n [farooq@rakmhsu.ac.ae](farooq@rakmhsu.ac.ae)[ ](farooq@rakmhsu.ac.ae)Imran Rangraze,  \n [imranrashid@rakmhsu.ac.ae](imranrashid@rakmhsu.ac.ae)[ ](imranrashid@rakmhsu.ac.ae)RECEIVED 10 November 2025 REVISED 20 January 2026 ACCEPTED 21 January 2026 PUBLISHED 10 February 2026  \nCITATION  \nWali AF, Rangraze I, Khan S, Mufti UB,  \nEl-Tanani M and Rizzo M (2026) Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.  \nFront. Pharmacol. 17:1736380 .  \ndoi: 10.3389/fphar.2026.1736380  \nCOPYRIGHT  \n© 2026 Wali, Rangraze, Khan, Mufti, El-Tanani and Rizzo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nReassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies  \nAdil Farooq Wali 1*, Imran Rangraze 2*, Shehla Khan 3,  \nUwais Bashir Mufti 4, Mohamed El-Tanani 1 and Manfredi Rizzo 2,5  \n1RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras AlKhaimah, United Arab Emirates, 2Department of Internal Medicine, RAK College of Medical Sciences, RAK Medical and Health Sciences, Ras AlKhaimah, United Arab Emirates, 3Department of Psychiatry, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras AlKhaimah, United Arab Emirates, 4Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5School of Medicine, PROMISE Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medicinal Specialties, University of Palermo, Palermo, Italy  \nBackground and Objectives: Glucagon-like peptide-1 receptor agonists (GLP- 1 RAs) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity. While their metabolic benefits are established, concerns persist about a possible link with gastrointestinal (GI) cancers. This study aimed to clarify the association between GLP-1 RA use and GI cancer risk.  \nMaterials and Methods: A systematic search of PubMed, Embase, and Scopus till August 2024 identified randomized controlled trials (RCTs) reporting GI cancer outcomes. Ninety-three RCTs with 1.85 million participants were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, with subgroup analyses by cancer type and exposure duration.  \nResults: GLP-1 RA use was not associated with an increased overall risk of GI cancers (HR 0. 81: 95% CI: 0.68–0. 96) . Subgroup analyses indicated reduced risks of colorectal cancer (HR 0. 81: 95% CI: 0.68–0. 96) and liver cancer (HR: 0.74; 95% CI: 0.62–0. 88) . Pancreatic cancer risk was not significantly elevated (HR: 0.78; 95% CI: 0.61–0. 95) . Findings were consistent across sensitivity analyses. Conclusion: This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously. These results support the continued safe use of GLP-1 RAs in T2DM and obesity, although longer trials with cancer-specific endpoints are warranted. This review was registered","cbCaiph8W3ItebzD","https://ap.wps.com/l/cbCaiph8W3ItebzD","pdf",3023608,14,"English","# Background and Objectives\n# Materials and Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What question does the review address about GLP-1 receptor agonists?\",\"answer\":\"It evaluates whether GLP-1 RA use is associated with the risk of gastrointestinal cancers.\"},{\"question\":\"How many randomized controlled trials and participants were included?\",\"answer\":\"Ninety-three randomized controlled trials with 1.85 million participants were included.\"},{\"question\":\"What did the meta-analysis find about overall gastrointestinal cancer risk?\",\"answer\":\"GLP-1 RA use was not associated with an increased overall risk of gastrointestinal cancers (HR 0.81; 95% CI 0.68–0.96).\"},{\"question\":\"Were there any cancer-specific findings in subgroup analyses?\",\"answer\":\"Yes. Colorectal and liver cancer risks were reduced in subgroup analyses, while pancreatic cancer risk was not significantly elevated; these findings should be interpreted cautiously.\"}]","Reassessing cancer risk with GLP-1 receptor agonists - a comprehensive meta-analysis of gastrointestinal malignancies | PDF",1790107050,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a2eaa76651e0258a4c3cd35347897bd.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fa720c135bc56d3c1a4bfec46175199.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffc09d59f389fddaba75361c0a5fd9a0.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72d3721410bf81aee31e5f6a407e425b.webp",980,1385]